CapmatinibAcquired MET D1228H mutation: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2026卷 / 1期
关键词：
D O I：
10.1007/s40278-024-66936-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：73 / 73
相关论文
共 50 条
  • [1] Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma
    Li, Xiuzhen
    Lu, Yuefei
    Zhao, Jie
    Yu, Yinghui
    Tian, Heshen
    Zhu, Hao
    Li, Wen
    Xia, Yang
    Chen, Laijuan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (08)
  • [2] Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
    Zhu, Jinlian
    Chen, Jie
    Liu, Wei
    Zhang, Junling
    Gu, Yulan
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 123 - 128
  • [3] CrizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer: case report
    Reactions Weekly, 2018, 1718 (1) : 82 - 82
  • [4] A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case report
    Kuang, Yukun
    Wang, Jiyu
    Xu, Peihang
    Zheng, Yifan
    Bai, Lihong
    Sun, Xue
    Li, Zimu
    Gan, Runjing
    Li, Huixia
    Ke, Zunfu
    Tang, Kejing
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [5] MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
    Tsai, Jonathan M.
    Hata, Aaron N.
    Lennerz, Jochen K.
    ONCOLOGIST, 2021, 26 (12): : E2297 - E2301
  • [6] Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
    Pruis, Melinda A.
    Paats, M. S.
    Geurts, W. R. R.
    Dubbink, H. J.
    Dingemans, A-M C.
    JCO PRECISION ONCOLOGY, 2021, 5 : 849 - 853
  • [7] Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
    Wang, Yu
    Chen, Zheng
    Han, Xiao
    Li, Jiamei
    Guo, Honglin
    Shi, Junping
    ONCOLOGIST, 2021, 26 (03): : 178 - 181
  • [8] Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
    Bahcall, Magda
    Sim, Taebo
    Paweletz, Cloud P.
    Patel, Jyoti D.
    Alden, Ryan S.
    Kuang, Yanan
    Sacher, Adrian G.
    Kim, Nam Doo
    Lydon, Christine A.
    Awad, Mark M.
    Jaklitsch, Michael T.
    Sholl, Lynette M.
    Jaenne, Pasi A.
    Oxnard, Geoffrey R.
    CANCER DISCOVERY, 2016, 6 (12) : 1334 - 1341
  • [9] Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer
    Parsons, Benjamin M.
    Meier, David R.
    Richmond, Craig S.
    Gurda, Grzegorz T.
    Lofgren, Kristopher A.
    Burkard, Mark E.
    Deming, Dustin A.
    Kenny, Paraic A.
    CLINICAL BREAST CANCER, 2020, 20 (04) : E433 - E438
  • [10] Cabozantinib/crizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer and progression of disease with various toxicities
    Reactions Weekly, 2022, 1887 (1) : 164 - 164
12345